News

Top-line results from the prospective, global, multi-center Phase 3 study demonstrated that BAX 855 met its primary endpoint in the control and prevention of bleeding, routine prophylaxis and

The financing included new investors RusnanoMedInvest (RMI) and WuXi PharmaTech Corporate Ventures. All previous investors including Canaan Partners and Correlation Ventures also participated in the round. The financing

In the study, Dr. Joshua Atkins, M.D., and colleagues from the Department of Anesthesiology and Critical Care, Perelman School of Medicine at the University of Pennsylvania in Philadelphia,

With this acquisition, Roche is eyeing to expand its offerings and bolster its presence in the treatment of deadly lung diseases. The company’s offer of $74 a share

The firms will evaluate the use of Advaxis’ Lm-LLO cancer immunotherapy, ADXS-PSA, in combination with Merck’s pembrolizumab in the Phase I/Phase II trial. The trial will assess the

This patent, when issued, will be valid until at least 2026. Additional patents claiming the BL-7010 composition and uses thereof are granted or pending in the US, Europe,

In the Phase 2a trial, all three doses of CCH (low (0.06mg), mid (0.48mg) and high (0.84mg)) showed an improvement in the appearance of cellulite as measured by

These patents have issued over the last several months from the intellectual property licensed by Dicerna from the City of Hope (COH) estate in November 2007. The newly

Under the new EMSA, Sucampo receives a new, lower price for certain components of or finished product of lubiprostone globally, except for the United States and Canada until